This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space
by Zacks Equity Research
Intercept (ICPT) stock gains as it becomes the forerunner in the NASH drug race.
Global Blood's (GBT) Oxbryta Secures FDA Approval for SCD
by Zacks Equity Research
Global Blood's (GBT) Oxbryta wins the FDA nod to address sickle cell disease in patients aged 12 years and above. The approval comes three months ahead of schedule.
Why Biotech ETFs Surged in Monday's Trading Session
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to drive the biotech market.
4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal
by Kinjel Shah
Here are four stocks that boast promising prospects and are most likely to be takeout targets.
Roche's NDA for SMA Drug Risdiplam Gets Priority Review
by Zacks Equity Research
The FDA accepts Roche's (RHHBY) NDA for risdiplam under a priority review to treat spinal muscular atrophy. A verdict is pending on May 24, 2020.
A Day of Mergers: TIF, AMTD, MDCO & More
by Zacks Equity Research
A Day of Mergers: TIF, AMTD, MDCO & More
Biggest Merger Monday in Awhile: TIF, AMTD, MDCO & More
by Mark Vickery
While Tiffany's agrees to terms with French luxury brand LVMH, Schwab buys Ameritrade, Novartis takes Medicines Co. and more.
Novartis (NVS) to Acquire The Medicines Company for $9.7B
by Zacks Equity Research
Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.
The Medicines Company to be Acquired by Novartis for $9.7B
by Zacks Equity Research
The Medicines Company (MDCO) agrees to the $85 per share or $9.7-billion acquisition offer from Novartis.
Pharma Stock Roundup: FDA Nod to NVS' & AZN's Drugs, BMY-CELG Merger Closes
by Kinjel Shah
The FDA approves Novartis' (NVS) sickle cell disease candidate Adakveo and AstraZeneca's (AZN) Calquence for chronic lymphocytic leukemia. Bristol-Myers (BMY) completes $74 billion-buyout of Celgene.
Medicines Company Up on Rumors of Potential Buyout by Novartis
by Zacks Equity Research
The Medicines Company (MDCO) is rumored to attract acquisition offers after impressive data readouts from three pivotal studies on PCSK9 inhibitor candidate, inclisiran.
Merck's Heart Failure Candidate Meets Goal in Phase III Study
by Zacks Equity Research
Merck (MRK) and German partner Bayer's vericiguat reduces the risk of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure.
Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex
by Zacks Equity Research
Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline.
Novartis Receives FDA Nod for Adakveo in Sickle Cell Disease
by Zacks Equity Research
Novartis (NVS) gets FDA nod for Adakveo to reduce the frequency of pain crises in adult and pediatric SCD patients.
Jazz's (JAZZ) Sleep Drug Sunosi Nears Approval in Europe
by Zacks Equity Research
Jazz's (JAZZ) sleep drug, Sunosi, which is under review in Europe, receives recommendation for approval from the CHMP.
The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics
Top Analyst Reports for Microsoft, Novartis & Novo Nordisk
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Novartis (NVS) and Novo Nordisk (NVO).
Roche's SMA Drug Meets Primary Endpoint in Pivotal Study
by Zacks Equity Research
Roche's (RHHBY) risdiplam meets primary endpoint in SUNFISH study in SMA patients.
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
Chegg, C.H. Robinson Worldwide, Tilray, Anheuser-Busch InBev and Novartis highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Chegg, C.H. Robinson Worldwide, Tilray, Anheuser-Busch InBev and Novartis highlighted as Zacks Bull and Bear of the Day
Novartis' Generics Unit to Buy Aspen's Japanese Operations
by Zacks Equity Research
Novartis (NVS) inks a deal to acquire the Japanese business of Aspen Global Incorporated.
Tilray (TLRY) Set to Report Q3 Results: Will the Stock Continue to Plunge?
by Christopher Vargas
Tilray (TLRY) is set to report its third quarter results after the closing bell Tuesday, November 12.
Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Aduro's (ADRO) loss misses estimates in Q3 while revenues almost match the mark.
Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products
by Kinjel Shah
Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.
Puma (PBYI) Q3 Earnings Beat, Nerlynx Sales Weak, Stock Down
by Zacks Equity Research
Puma Biotech (PBYI) incurs narrower loss in Q3. Sales of Nerlynx decline sequentially. Stock drops 18%.